Article: Acadia executive moves to start new company.(Acadia Pharmaceuticals Inc.)(Brief article)

The chief scientific officer of Acadia Pharmaceuticals Inc., Mark Brann, is leaving the company to start Abbey Pharmaceuticals, which will focus on medications for substance abuse, especially alcoholism.

Acadia is providing $1 million upon Abbey's completion of an external equity financing.

Brann also resigned from his board member position at Acadia, which has around 100 ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!